Can China and the U.S. work together to cure cancer?
Illustration by Sam Ward
In the early afternoon of June 5, 2017, at the annual American Society of Clinical Oncology (ASCO) conference, hundreds of the world’s leading cancer researchers, pharmaceutical firms and biotech investors focused their attention on a virtually unknown Chinese firm called Legend Biotech.
At that time, the U.S. company Johnson & Johnson’s $10.6 billion research and development budget amounted to $3 billion more than all Chinese pharmaceutical firms combined. But despite hailing from a
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
From Mike Mansfield to Max Baucus and Steve Daines, Montana has been the unlikely source of America’s most influential China-hand senators over the past half-century. But amidst spy balloons, trade wars and mutual paranoia, being a proponent for rational and beneficial relations between the two countries has never been harder.
The former CIA officer says Washington has lacked a clear strategy towards intelligence on China, in contrast to Beijing’s approach — and that Congress needs to act.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
